A study in the New England Journal of Medicine indicates that immunotherapy with dostarlimab may allow some early-stage cancer patients to avoid surgery; 82 of 103 participants showed significant improvement. While all 49 patients with early-stage rectal cancer avoided surgery after six months of treatment, the study’s small, specific patient group raises questions about broader applicability. Researchers aim to expand trials to include more patients and different cancer types to potentially transform treatment standards.
